NCT04729387 2026-03-13
Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected
Novartis
Phase 3 Terminated
Clinical Trials
706 trialsNCT06038539 2026-03-13
Efficacy and Safety of the Proposed Biosimilar Pertuzumab (PERT-IJS) Versus EU-Perjeta® Along With Trastuzumab and Chemotherapy (Carboplatin and Docetaxel) as Neoadjuvant Treatment in Chemotherapy naïve Patients With Early Stage or Locally Advanced HR Negative and HER2 Positive Breast Cancer
Biocon Limited
Phase 3 Terminated
NCT01366612 2026-03-09
FLUBUTBI
Hackensack Meridian Health
Phase 3 Terminated
NCT04777851 2026-03-09
REPLACE
Translational Research in Oncology
Phase 3 Terminated
NCT04222972 2026-03-05
AcceleRET-Lung
Hoffmann-La Roche
Phase 3 Terminated
NCT06587451 2026-02-24
Integrated Pharmacokinetics (PK)/Efficacy, Safety, and Immunogenicity Study to Demonstrate Similarity of JPB898, a Proposed Biosimilar to Nivolumab, to Opdivo® in Combination With Yervoy®
Sandoz
Phase 3 Terminated
NCT05171049 2026-02-23
ASTER
Anthos Therapeutics, Inc.
Phase 3 Terminated
NCT04876651 2026-02-20
The Present Study Aims to Compare Patients Who Receive the Investigational Product (177Lu-DOTA-rosopatamab) Plus Standard of Care, in Comparison to Standard of Care Only
Telix Pharmaceuticals (Innovations) Pty Limited
Phase 3 Terminated
NCT05386550 2026-02-19
Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants (XRAY VISION)
EMD Serono
Phase 3 Terminated
NCT05223647 2026-01-28
TRIPLEX
Norwegian University of Science and Technology
Phase 3 Terminated
NCT03926624 2026-01-22
Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage
Delta-Fly Pharma, Inc.
Phase 3 Terminated
NCT04266301 2026-01-13
STIMULUS-MDS2
Novartis
Phase 3 Terminated
NCT05002569 2026-01-08
RELATIVITY-098
Bristol-Myers Squibb
Phase 3 Terminated
NCT05675319 2026-01-05
AlloRelapseMM
Universitätsklinikum Hamburg-Eppendorf
Phase 3 Terminated
NCT03042169 2025-12-23
SURGIGAST
University Hospital, Lille
Phase 3 Terminated
NCT03924869 2025-12-11
KEYNOTE-867
Merck Sharp & Dohme LLC
Phase 3 Terminated
NCT06280196 2025-12-02
A Study to Evaluate PK, Efficacy, and Safety of BAT3306 Plus Chemo and Compare With Keytruda®(EU/US) in Participants With IV nqNSCLC
Bio-Thera Solutions
Phase 3 Terminated
NCT01546571 2025-10-24
MAVIS
Polynoma LLC
Phase 3 Terminated
NCT04459715 2025-10-08
A Study of Xevinapant (Debio 1143) in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Participants With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX)
EMD Serono
Phase 3 Terminated
NCT03216187 2025-10-07
PREVENT
University Hospital, Geneva
Phase 3 Terminated
NCT03598712 2025-10-06
CLODIS
Centre Francois Baclesse
Phase 3 Terminated
NCT04161885 2025-10-06
VIALE-T
AbbVie
Phase 3 Terminated
NCT04458909 2025-10-03
Testing the Addition of an Anti-cancer Immune Therapy Drug (Nivolumab) to the Usual Chemotherapy Treatment (Cisplatin or Carboplatin With Gemcitabine) for Recurrent or Metastatic Nasopharyngeal Cancer
National Cancer Institute (NCI)
Phase 3 Terminated
NCT04551053 2025-10-02
To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)
Incyte Corporation
Phase 3 Terminated
NCT05604170 2025-10-01
Open-label Study of Adjunctive GNX Treatment in Children and Adults With TSC-related Epilepsy
Marinus Pharmaceuticals
Phase 3 Terminated
NCT02967692 2025-09-18
COMBI-i
Novartis
Phase 3 Terminated
NCT04149574 2025-09-16
CheckMate 7G8
Bristol-Myers Squibb
Phase 3 Terminated
NCT04478266 2025-09-11
AMEERA-5
Sanofi
Phase 3 Terminated
NCT05132569 2025-09-09
URSA
Sanofi
Phase 3 Terminated
NCT06125028 2025-09-05
LYMFOR
Pentixapharm AG
Phase 3 Terminated
NCT03149575 2025-09-04
STAR-3
Kintara Therapeutics, Inc.
Phase 3 Terminated
NCT04815083 2025-09-03
Fluorescence Imaging of Carcinoma During Breast Conserving Surgery
SBI ALApharma Canada, Inc.
Phase 3 Terminated
NCT05092360 2025-08-28
ARTISTRY-7
Mural Oncology, Inc
Phase 3 Terminated
NCT03656536 2025-08-24
FIGHT-302
Incyte Corporation
Phase 3 Terminated
NCT02363400 2025-08-19
A Phase III Trial in NPC With Post-radiation Detectable Plasma EBV DNA
National Health Research Institutes, Taiwan
Phase 3 Terminated
NCT05328908 2025-08-13
RELATIVITY-123
Bristol-Myers Squibb
Phase 3 Terminated
NCT04740918 2025-08-08
KATE3
Hoffmann-La Roche
Phase 3 Terminated
NCT03194646 2025-07-28
ASTEROID 6
Bayer
Phase 3 Terminated
NCT04474925 2025-07-18
Pre- Versus Post-operative SRS for Resectable Brain Metastases
AHS Cancer Control Alberta
Phase 3 Terminated
NCT05142904 2025-07-17
RABITO
Rijnstate Hospital
Phase 3 Terminated
NCT04752332 2025-07-15
eMonarcHER
Eli Lilly and Company
Phase 3 Terminated
NCT06643117 2025-06-26
Lotus
Formycon AG
Phase 3 Terminated
NCT04503668 2025-06-18
Olanzapine for the Prevention of Chemotherapy Induced Nausea and Vomiting in Gynecologic Oncology Patients
University of Michigan Rogel Cancer Center
Phase 3 Terminated
NCT02010957 2025-06-10
FAMIAN
Wuerzburg University Hospital
Phase 3 Terminated
NCT04588246 2025-06-06
Comparing Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in Patients With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic Radiosurgery
NRG Oncology
Phase 3 Terminated
NCT04261777 2025-06-03
Ferumoxtran-10-enhanced MRI in Prostate Cancer Patients
Saving Patients' Lives Medical B.V.
Phase 3 Terminated
NCT06108739 2025-06-03
ATG Plus Low-dose PT-Cy for GVHD Prevention
Peking University People's Hospital
Phase 3 Terminated
NCT02467582 2025-05-16
Adjuvant Aspirin Treatment for Colon Cancer Patients
Swiss Cancer Institute
Phase 3 Terminated
NCT04427072 2025-05-16
GeoMETry-III
Novartis
Phase 3 Terminated
NCT05930938 2025-05-09
XXL_2022-01
Groupe Oncologie Radiotherapie Tete et Cou
Phase 3 Terminated